331,900 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 331,900 shares of the biotechnology company's stock, valued at approximately $1,908,000. Enanta Pharmaceuticals makes up about 1.5% of Stonepine Capital Management LLC's investment portfolio, making the stock its 20th largest position. Stonepine Capital Management LLC owned approximately 1.56% of Enanta Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in ENTA. RA Capital Management L.P. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth $5,968,000. Millennium Management LLC boosted its position in shares of Enanta Pharmaceuticals by 22.7% in the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock valued at $5,158,000 after purchasing an additional 165,692 shares during the period. Dimensional Fund Advisors LP increased its stake in Enanta Pharmaceuticals by 52.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company's stock worth $1,708,000 after purchasing an additional 102,646 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Enanta Pharmaceuticals by 51.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock worth $1,668,000 after buying an additional 98,285 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company's stock worth $2,524,000 after buying an additional 85,082 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock traded up $0.07 during trading hours on Friday, hitting $5.82. The company had a trading volume of 21,942 shares, compared to its average volume of 347,446. The firm's fifty day moving average is $5.43 and its 200-day moving average is $6.51. The firm has a market capitalization of $124.41 million, a P/E ratio of -1.17 and a beta of 0.81. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The firm had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENTA. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.